Recent Changes in Chronic Kidney Disease-Mineral and Bone Disorders and Associated Fractures After Kidney Transplantation

被引:25
作者
Perrin, Peggy [1 ]
Kiener, Clotilde [1 ]
Javier, Rose-Marie [2 ]
Braun, Laura [1 ]
Cognard, Noelle [1 ]
Gautier-Vargas, Gabriela [1 ]
Heibel, Francoise [1 ]
Muller, Clotilde [1 ]
Olagne, Jerome [1 ]
Moulin, Bruno [1 ]
Ohlmann, Sophie [1 ]
机构
[1] Univ Hosp, Nephrol Transplantat Dept, Strasbourg, France
[2] Univ Hosp, Dept Rheumatol, Strasbourg, France
关键词
PERSISTENT SECONDARY HYPERPARATHYROIDISM; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; RENAL-TRANSPLANT; VITAMIN-D; RECIPIENTS; MANAGEMENT; CINACALCET; RISK; SUPPLEMENTATION; HEMODIALYSIS;
D O I
10.1097/TP.0000000000001449
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background The management of chronic kidney disease-mineral and bone disorders has recently changed. We investigated the modifications of chronic kidney disease-mineral and bone disorder with a special focus on the incidence of fractures in the first year after kidney transplantation (KT). Methods We retrospectively compared 2 groups of patients who consecutively underwent transplantation at our center 5 years from each other. Group 1 consisted of patients (n = 152) transplanted between 2004 and 2006, whereas patients in group 2 (n = 137) underwent KT between 2009 and 2011. Results During the end-stage renal disease phase at the time of transplant, cinacalcet, and native vitamin D were used significantly more frequently in group 2. Median intact parathyroid hormone levels were lower and severe hyperparathyroidism decreased significantly. Vitamin D deficiency dropped from 64% to 20%. After transplantation, persistent hyperparathyroidism (parathyroid hormone > 130 ng/L) and bone turnover markers were significantly reduced in group 2. Native vitamin D supplementation increased over time, whereas the use of active vitamin D was unchanged. The 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels were significantly higher. The fracture incidence at 1 year decreased significantly (3.1% vs 9.1%; P = 0.047). No steroid sparing was observed in group 2. Bisphosphonates after KT were more frequently used in group 2. Conclusions Recent changes in clinical practice are associated with reductions in pretransplant and posttransplant hyperparathyroidism, vitamin D deficiency, and fracture risk after KT.
引用
收藏
页码:1897 / 1905
页数:9
相关论文
共 40 条
[1]   Can DXA Predict Fractures in Renal Transplant Patients? [J].
Akaberi, S. ;
Simonsen, O. ;
Lindergard, B. ;
Nyberg, G. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (12) :2647-2651
[2]  
ALEXEEVA L, 1994, WHO TECH REP SER, V843, P1
[3]   Predicting Deficiency of Vitamin D in Renal Transplant Recipients in Northern Climates [J].
Beique, Lesley C. ;
Kline, Gregory A. ;
Dalton, Bruce ;
Duggan, Kimberly ;
Yilmaz, Serdar .
TRANSPLANTATION, 2013, 95 (12) :1479-1484
[4]   Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate [J].
Coco, M ;
Glicklich, D ;
Faugere, MC ;
Burris, L ;
Bognar, I ;
Durkin, P ;
Tellis, V ;
Greenstein, S ;
Schechner, R ;
Figueroa, K ;
McDonough, P ;
Wang, GD ;
Malluche, H .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (10) :2669-2676
[5]   Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients [J].
Courbebaisse, Marie ;
Thervet, Eric ;
Souberbielle, Jean Claude ;
Zuber, Julien ;
Eladari, Dominique ;
Martinez, Frank ;
Mamzer-Bruneel, Marie-France ;
Urena, Pablo ;
Legendre, Christophe ;
Friedlander, Gerard ;
Prie, Dominique .
KIDNEY INTERNATIONAL, 2009, 75 (06) :646-651
[6]   Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation [J].
El-Amm, Jose-Marie ;
Doshi, Mona D. ;
Singh, Atul ;
Migdal, Stephen ;
Morawski, Katherina ;
Sternbauer, Diane ;
Cincotta, Elizabeth ;
West, Miguel S. ;
Losanoff, Julian E. ;
Gruber, Scott A. .
TRANSPLANTATION, 2007, 83 (05) :546-549
[7]   A Randomized Study Evaluating Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients With Persistent Hyperparathyroidism [J].
Evenepoel, P. ;
Cooper, K. ;
Holdaas, H. ;
Messa, P. ;
Mourad, G. ;
Olgaard, K. ;
Rutkowski, B. ;
Schaefer, H. ;
Deng, H. ;
Torregrosa, J. V. ;
Wuthrich, R. P. ;
Yue, S. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (11) :2545-2555
[8]   Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study [J].
Evenepoel, P ;
Claes, K ;
Kuypers, D ;
Maes, B ;
Bammens, B ;
Vanrenterghem, Y .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (05) :1281-1287
[9]   Localization, Etiology and Impact of Calcium Phosphate Deposits in Renal Allografts [J].
Evenepoel, P. ;
Lerut, E. ;
Naesens, M. ;
Bammens, B. ;
Claes, K. ;
Kuypers, D. ;
Vermeersch, P. ;
Meijers, B. ;
Van Damme, B. ;
Vanrenterghem, Y. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (11) :2470-2478
[10]   Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation [J].
Fan, SLS ;
Kumar, S ;
Cunningham, J .
KIDNEY INTERNATIONAL, 2003, 63 (06) :2275-2279